Trade Summary

2 weeks ago, Orbimed Advisors LLC, serving as 10% owner at Traws Pharma, Inc. (TRAW), purchased 597,729 shares at $1.67 per share, for a total transaction value of $998,207.00. Following this transaction, Orbimed Advisors LLC now holds 1,203,250 shares of TRAW.

This purchase represents a 99.00% increase in Orbimed Advisors LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 16, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, April 28, 2026, 12 days after the trade was made.

Traws Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.